KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Revenue (2016 - 2025)

Fulgent Genetics' Revenue history spans 11 years, with the latest figure at $83.3 million for Q4 2025.

  • For Q4 2025, Revenue rose 9.34% year-over-year to $83.3 million; the TTM value through Dec 2025 reached $322.7 million, up 13.83%, while the annual FY2025 figure was $322.7 million, 13.83% up from the prior year.
  • Revenue for Q4 2025 was $83.3 million at Fulgent Genetics, down from $84.1 million in the prior quarter.
  • Across five years, Revenue topped out at $359.4 million in Q1 2021 and bottomed at $64.5 million in Q1 2024.
  • The 5-year median for Revenue is $82.6 million (2025), against an average of $125.3 million.
  • The largest annual shift saw Revenue surged 4536.0% in 2021 before it tumbled 79.34% in 2023.
  • A 5-year view of Revenue shows it stood at $251.7 million in 2021, then tumbled by 73.1% to $67.7 million in 2022, then grew by 4.14% to $70.5 million in 2023, then rose by 8.1% to $76.2 million in 2024, then grew by 9.34% to $83.3 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Revenue are $83.3 million (Q4 2025), $84.1 million (Q3 2025), and $81.8 million (Q2 2025).